Immunotoxicological effects of streptozotocin and alloxan: In vitro and in vivo studies

Immunology Letters

Volumn 163, Issue 2, 2015, Pages 193-198

  Diab, Randa A Hadi ^a,b   Fares, Mona ^a   Abedi Valugerdi, Manuchehr ^a   Kumagai Braesch, Makiko ^a   Holgersson, Jan ^c   Hassan, Moustapha ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b AHFAD UNIVERSITY FOR WOMEN   (Sudan)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alloxan; Diabetes; Islets; Streptozotocin; Toxicity

Indexed keywords

ALLOXAN; CONCANAVALIN A; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 2; STREPTOZOCIN; CYTOKINE; GLUCOSE BLOOD LEVEL;

ALLOXAN-INDUCED DIABETES MELLITUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; GLUCOSE BLOOD LEVEL; GRAFT SURVIVAL; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MIXED LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; RAT; SPLEEN CELL; SPLEEN WEIGHT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HL 60 CELL LINE; IC50; IMMUNOLOGY; K562 CELL LINE; LEWIS RAT; METABOLISM; MORTALITY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SPLEEN; SURVIVAL RATE; TIME; TUMOR CELL LINE; XENOGRAFT;

ALLOXAN; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ISLETS OF LANGERHANS TRANSPLANTATION; K562 CELLS; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; ORGAN SIZE; RATS, INBRED LEW; SPLEEN; STREPTOZOCIN; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84920982917     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.12.006     Document Type: Article

References (23)

1. Gorus F.K., Malaisse W.J., Pipeleers D.G. Selective uptake of alloxan by pancreatic B-cells. Biochem J 1982, 208:513-515.
2. Weaver D.C., McDaniel M.L., Lacy P.E. Alloxan uptake by isolated rat islets of Langerhans. Endocrinology 1978, 102:1847-1855.
3. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001, 50:537-546.
4. Elsner M., Gurgul-Convey E., Lenzen S. Relative importance of cellular uptake and reactive oxygen species for the toxicity of alloxan and dialuric acid to insulin-producing cells. Free Radic Biol Med 2006, 41:825-834.
5. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008, 51:216-226.
6. Weiss R.B. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 1982, 66:427-438.
7. White F.R. Streptozotocin. Cancer Chemother Rep Part I 1963, 30:49-53.
8. Gaulton G.N., Schwartz J.L., Eardley D.D. Assessment of the diabetogenic drugs alloxan and streptozotocin as models for the study of immune defects in diabetic mice. Diabetologia 1985, 28:769-775.
9. Muller Y.D., Golshayan D., Ehirchiou D., Wyss J.C., Giovannoni L., Meier R., et al. Immunosuppressive effects of streptozotocin-induced diabetes result in absolute lymphopenia and a relative increase of T regulatory cells. Diabetes 2011, 60:2331-2340.
10. Rubinstein R., Genaro A.M., Motta A., Cremaschi G., Wald M.R. Impaired immune responses in streptozotocin-induced type I diabetes in mice. Involvement of high glucose. Clin Exp Immunol 2008, 154:235-246.
11. Sakowicz-Burkiewicz M., Kocbuch K., Grden M., Szutowicz A., Pawelczyk T. Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes. Immunology 2006, 118:402-412.
12. Koulmanda M., Qipo A., Auchincloss H., Smith R.N. Effects of streptozotocin on autoimmune diabetes in NOD mice. Clin Exp Immunol 2003, 134:210-216.
13. Eizirik D.L., Pipeleers D.G., Ling Z., Welsh N., Hellerström C., Andersson A. Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. Proc Natl Acad Sci 1994, 91:9253-9256.
14. Tyrberg B., Andersson A., Håkan Borg L.A. Species differences in susceptibility of transplanted and cultured pancreatic islets to the β-cell toxin alloxan. Gen Comp Endocrinol 2001, 122:238-251.
15. Lenzen S., Munday R. Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin. Biochem Pharmacol 1991, 42:1385-1391.
16. Patterson J.W., Lazarow A. Alloxan and dialuric acid; their stabilities and ultraviolet absorption spectra. J Biol Chem 1949, 177:187-196.
17. Hammarstrom L., Hellman B., Ullberg S. On the accumulation of alloxan in the pancreatic beta-cells. Diabetologia 1967, 3:340-344.
18. Hugues S., Mougneau E., Ferlin W., Jeske D., Hofman P., Homann D., et al. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity 2002, 16:169-181.
19. Nichols W.K., Spellman J.B., Vann L.L., Daynes R.A. Immune responses of diabetic animals. Direct immunosuppressant effects of streptozotocin in mice. Diabetologia 1979, 16:51-57.
20. Takayama Y., Ichikawa T., Maki T. Effect of STZ administration on islet isograft and allograft survival in NOD mice. Diabetes 1993, 42:324-329.
21. + T cells. J Interferon Cytokine Res 2008, 28:611-622.
22. Kumagai-Braesch M., Ekberg H., Wang F., Osterholm C., Ehrnfelt C., Sharma A., et al. Anti-LFA-1 improves pig islet xenograft function in diabetic mice when long-term acceptance is induced by CTLA4Ig/anti-CD40L. Transplantation 2007, 83:1259-1267.
23. Diab R.A., Hassan M., Tibell A., Holgersson J., Kumagai-Braesch M. Rat islets are not rejected by anti-islet antibodies in mice treated with costimulation blockade. Xenotransplantation 2014, 21(4):353-366.